Recruiting

Antibiotics Combination

Sponsor:

Intermountain Health Care, Inc.

Code:

NCT07376889

Conditions

Staphylococcus Aureus Bacteremia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Study Details

Brief summary:

The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

Conditions

Staphylococcus Aureus Bacteremia

Study ID

NCT07376889

Start date

Feb 1, 2026

Status verified date

Aug, 2026

Completion date

Jan, 2029

Anticipated

Primary completion date

Jan, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥18 years
  • Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment
  • Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected:

1. on or during the index admission to an IH hospital, or
2. in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or
3. at a non-IH network hospital within 24 hours of subsequent transfer to an IH hospital

Exclusion Criteria:
  • Patient requests that patient health data not be included in the analysis

Study Design

Enrollment

2096 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MSSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy

experimental: Patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Patients with methicillin-resistant S. aureus bacteremia (MRSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MRSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy

Interventions

Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.

Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Vancomycin or daptomycin, per discretion of the treating physician

Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem

Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Daptomycin plus ceftaroline

Primary outcome measure

  • Desirability of Outcome Ranking (DOOR) [ Time Frame: From enrollment to 30 days post enrollment ]

Central Contacts and Locations

Central contacts

Brandon J Webb, MD

801-507-7781Brandon.Webb@imail.org

Whitney R Buckel, PharmD

801-284-1046Whitney.Buckel@imail.org

Locations

Intermountain Medical Center

Recruiting

Murray, Utah, United States, 84107

Contacts

Brandon J Webb, MD

801-507-7781Brandon.Webb@imail.org

Whitney R Buckel, PharmD

801-284-1046Whitney.Buckel@imail.org

Principal Investigator:

Brandon J Webb, MD

More Information

Sponsor

Intermountain Health Care, Inc.

Last update posted

Aug 25, 2026

Last verified

Aug, 2026

Keywords

  • Combination antibiotic therapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Intermountain Health Care, Inc. on 2026-08-25.